Lihui Wang

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 16

Top Venues

EMBO molecular medicine

British journal of cancer

Journal of natural products

Science advances

This page only lists publications with an associated author ORCID identifier.

Publications

Yingxi Zhao, Yonghao Zheng, Jinjiang Fu, Jiayu Zhang, Hui Shao, Shougeng Liu, Jiacheng Lai, Xue Zhou, Ruijuan Liang, Lina Jia, Wei Cui, Jingyu Yang, Chunfu Wu, Lihui Wang
KDM1A, a potent and selective target, for the treatment of DNMT3A-deficient non-small cell lung cancer. British journal of cancer (2024)
Yuan Yang, Zefei Li, Yidong Wang, Jiwei Gao, Yangyang Meng, Simeng Wang, Xiaoyao Zhao, Chengfang Tang, Weiming Yang, Yingjia Li, Jie Bao, Xinyu Fan, Jing Tang, Jingyu Yang, Chunfu Wu, Mingze Qin, Lihui Wang
The regulatory relationship between NAMPT and PD-L1 in cancer and identification of a dual-targeting inhibitor. EMBO molecular medicine 16 (4) (2024)
Zehui Tan, Ning Guo, Shuyu Liu, Jiandong Li, Yu Chen, Jianming Cui, Hongrui Lei, Nan Jiang, Lihui Wang, Xin Zhai
Discovery of Novel Non-nucleoside DOT1L R231Q Inhibitors with Improved Pharmacokinetic Properties and Anti-lung Cancer Efficacy. Journal of medicinal chemistry (2024)
Yuan Yang, Zefei Li, Yidong Wang, Jiwei Gao, Yangyang Meng, Simeng Wang, Xiaoyao Zhao, Chengfang Tang, Weiming Yang, Yingjia Li, Jie Bao, Xinyu Fan, Jing Tang, Jingyu Yang, Chunfu Wu, Mingze Qin, Lihui Wang
The regulatory relationship between NAMPT and PD-L1 in cancer and identification of a dual-targeting inhibitor. EMBO molecular medicine 16 (4) (2024)
Yuan Yang, Zefei Li, Yidong Wang, Jiwei Gao, Yangyang Meng, Simeng Wang, Xiaoyao Zhao, Chengfang Tang, Weiming Yang, Yingjia Li, Jie Bao, Xinyu Fan, Jing Tang, Jingyu Yang, Chunfu Wu, Mingze Qin, Lihui Wang
The regulatory relationship between NAMPT and PD-L1 in cancer and identification of a dual-targeting inhibitor. EMBO molecular medicine (2024)
Lei Zhao, Heyao Ma, Yuhui Jiang, Yingying Li, Li Qiao, Yu Chen, Xiaowen Jiang, Lihui Wang, Shu Wang, Xinyu Fan
Identification of an m6A Natural Inhibitor, Lobeline, That Reverses Lenvatinib Resistance in Hepatocellular Tumors. Journal of natural products 87 (8) (2024)
Lei Zhao, Heyao Ma, Yuhui Jiang, Yingying Li, Li Qiao, Yu Chen, Xiaowen Jiang, Lihui Wang, Shu Wang, Xinyu Fan
Identification of an m6A Natural Inhibitor, Lobeline, That Reverses Lenvatinib Resistance in Hepatocellular Tumors. Journal of natural products 87 (8) (2024)
Yingxi Zhao, Yonghao Zheng, Jinjiang Fu, Jiayu Zhang, Hui Shao, Shougeng Liu, Jiacheng Lai, Xue Zhou, Ruijuan Liang, Lina Jia, Wei Cui, Jingyu Yang, Chunfu Wu, Lihui Wang
KDM1A, a potent and selective target, for the treatment of DNMT3A-deficient non-small cell lung cancer. British journal of cancer 131 (4) (2024)
Lei Zhao, Heyao Ma, Yuhui Jiang, Yingying Li, Li Qiao, Yu Chen, Xiaowen Jiang, Lihui Wang, Shu Wang, Xinyu Fan
Identification of an m6A Natural Inhibitor, Lobeline, That Reverses Lenvatinib Resistance in Hepatocellular Tumors. Journal of natural products (2024)
Yingxi Zhao, Yonghao Zheng, Jinjiang Fu, Jiayu Zhang, Hui Shao, Shougeng Liu, Jiacheng Lai, Xue Zhou, Ruijuan Liang, Lina Jia, Wei Cui, Jingyu Yang, Chunfu Wu, Lihui Wang
KDM1A, a potent and selective target, for the treatment of DNMT3A-deficient non-small cell lung cancer. British journal of cancer 131 (4) (2024)
Yuan Yang, Zefei Li, Yidong Wang, Jiwei Gao, Yangyang Meng, Simeng Wang, Xiaoyao Zhao, Chengfang Tang, Weiming Yang, Yingjia Li, Jie Bao, Xinyu Fan, Jing Tang, Jingyu Yang, Chunfu Wu, Mingze Qin, Lihui Wang
The regulatory relationship between NAMPT and PD-L1 in cancer and identification of a dual-targeting inhibitor. EMBO molecular medicine 16 (4) (2024)
Yuan Yang, Zefei Li, Yidong Wang, Jiwei Gao, Yangyang Meng, Simeng Wang, Xiaoyao Zhao, Chengfang Tang, Weiming Yang, Yingjia Li, Jie Bao, Xinyu Fan, Jing Tang, Jingyu Yang, Chunfu Wu, Mingze Qin, Lihui Wang
The regulatory relationship between NAMPT and PD-L1 in cancer and identification of a dual-targeting inhibitor. EMBO molecular medicine 16 (4) (2024)
Yingxi Zhao, Yonghao Zheng, Jinjiang Fu, Jiayu Zhang, Hui Shao, Shougeng Liu, Jiacheng Lai, Xue Zhou, Ruijuan Liang, Lina Jia, Wei Cui, Jingyu Yang, Chunfu Wu, Lihui Wang
KDM1A, a potent and selective target, for the treatment of DNMT3A-deficient non-small cell lung cancer. British journal of cancer 131 (4) (2024)
Jiayu Zhang, Ting Yang, Mei Han, Xiaoxuan Wang, Weiming Yang, Ning Guo, Yong Ren, Wei Cui, Shangxiao Li, Yongshan Zhao, Xin Zhai, Lina Jia, Jing Y Yang, Chunfu Wu, Lihui Wang
Gain-of-function mutations in the catalytic domain of DOT1L promote lung cancer malignant phenotypes via the MAPK/ERK signaling pathway. Science advances 9 (22) (2023)
Jianmin Wang, Cheng Yang, Huashen Xu, Xinyu Fan, Lina Jia, Yang Du, Shougeng Liu, Wenjing Wang, Jie Zhang, Yu Zhang, Xiaoxue Wang, Zhongbo Liu, Jie Bao, Songping Li, Jingyu Yang, Chunfu Wu, Jing Tang, Guoliang Chen, Lihui Wang
The Interplay Between HIF-1α and EZH2 in Lung Cancer and Dual-Targeted Drug Therapy. Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2023)
Jiayu Zhang, Wenlong Zhou, Xiaoxuan Wang, Lihui Wang
The CRISPR-Cas9 system: a promising tool for discovering potential approaches to overcome drug resistance in cancer. RSC advances 8 (58) (2018)

Lihui Wang.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Lihui Wang